Literature DB >> 28551634

Combination of Radiofrequency Ablation and Glycated Chitosan as Treatment on a Syngeneic Breast Tumor Model.

Hsin-Yu Chiu1, Jyh-DER Leu2, Chun-Yuan Chang1, Yi-Jang Lee3,4, Wei R Chen5.   

Abstract

AIM: Effects of radiofrequency ablation (RFA) combining immunoadjuvant glycated chitosan (GC) on tumor control and potent cytokine responses were investigated in a syngeneic breast tumor model.
MATERIALS AND METHODS: Murine 4T1 breast carcinoma cells harboring the luciferase reporter gene were used to evaluate the tumor growth rate and metastasis in vivo using bioluminescent imaging. Plasma of RFA/GC-treated tumor-bearing mice was collected for ex vivo cytotoxicity analysis and mouse chemokine array assays.
RESULTS: Tumor growth and systemic metastasis were suppressed by combined RFA and GC when tumor size reached 300 mm3, not detected, however, when tumor size reached 800 mm3 The survival rate of mice bearing small tumors was also higher than that of large ones after RFA-GC treatment. Plasma extracted from RFA-GC-treated small tumor-bearing mice exhibited cytotoxicity on cultured 4T1 cells. Moreover, reduced tumor growth-related cytokines and increased antitumor-related cytokines were detected in the plasma collected.
CONCLUSION: RFA combining GC could control tumor progression with induced potent antitumor cytokine responses. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Glycated chitosan; antitumor; breast cancer; cytokine responses; radiofrequency ablation; syngeneic tumor model

Mesh:

Substances:

Year:  2017        PMID: 28551634     DOI: 10.21873/anticanres.11650

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  1 in total

1.  N-Dihydrogalactochitosan Potentiates the Radiosensitivity of Liver Metastatic Tumor Cells Originated from Murine Breast Tumors.

Authors:  Chung-Yih Wang; Chun-Yuan Chang; Chun-Yu Wang; Kaili Liu; Chia-Yun Kang; Yi-Jang Lee; Wei R Chen
Journal:  Int J Mol Sci       Date:  2019-11-08       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.